Production and development of multi-doses, with or without preservatives

To meet our clients’ needs and market demands, we offer a range of aseptic multi-dose filling solutions. Unither offers development and manufacturing services for technologies for preservative-free multi-doses (PFMD) and standard multi-dose (preserved).

Stérile
Sterile
Volume_Filling (1)
Filling volume: standard multi-dose (preserved): 1.5 to 15 ml / MDSC: 5 to 15 ml
Volume_Filling (2)
Bottle configurations: classic and soft bottles, with different bottle-and-cap combinations
Multidoses
personnalisation
Technologies: Aptar OSD® and Nemera Novelia®
solutions supensions
Formulation types: ophthalmic solutions and suspensions, otology products
statut
Product statuses: pharmaceuticals, medical devices, OTC, cosmetics ...

Benefits of multi-dose technology for ophthalmic products

Choosing multidose technology ensures continuity of chronic ophthalmic treatments.

  • Improved product tolerance
  • Prevention of microbial contamination for the entire treatment period
  • Complement to the BFS ophthalmic range
  • The vial is easier to transport than multiple single-dose vials and generates no product waste, making the format more environmentally friendly.
  • Calibrated drops
  • Easy to use
  • Suitable for chronic diseases
  • Suitable for a range of therapeutic areas: allergic, anti-infective, anti-inflammatory, glaucoma, dry eye syndrome (DES), ocular hygiene solutions, new chemical entities (NCE), etc.

Multi-dose manufacturing sites

Regulatory authorizations, standards and certifications: access the full list

Out-licensing - our turnkey documentation and products in Multi-Dose packaging

 Table: Out-licensing - our turnkey documentation and products in Multi-Dose packaging
Multi-dose Volume Category Status Dossier Country
Sodium Carmellose (CMC) 0.5% 10.15 ml Ocular lubricant MD October 2026 - ANVISA Brazil
Sodium Hyaluronate 0.15% 10 ml Ocular lubricant MD October 2026 - ANVISA Brazil
Sodium Carmellose (CMC) 0.5% + Sodium Hyaluronate 0.10% + Glycerol 0.9% 10 ml Ocular lubricant MD Q1 2027 - ANVISA Brazil
EYELEEN - Carragelose eye drops 3.2 mg/ml (Preservative free) 10 ml Ocular lubricant MD (IIa) CE Marking Contact us

End-to-end support from the initial phases: from concept to product

Manufacturing

From technology transfer to industrial manufacturing, from small clinical batches to commercial volumes.

Development

Formulation and analytical development, manufacture of clinical batches, stability studies, and expertise in ophthalmic development.

Out-licensing

Access medicines and medical devices that are ready to be registered and marketed.
 Content type:  Resource  Resource

Carragelose scientific publications

This list brings together the main scientific publications on iota-carrageenan and its applications in the fields of immunology and virology.It…
 Content type:  Resource  Resource

Carragelose Eyedrops - "Eyeleen"

Discover a New Approach to Dry Eye Relief Dry Eye Disease (DED) affects millions of people worldwide, often leading to…

Do you have any questions? - Consult our FAQ

Unither Pharmaceuticals provides complementary technologies for ophthalmic products, including preservative-free multidose (PFMD), multidose with preservatives, and Blow-Fill-Seal (BFS) sterile single-dose formats. This portfolio enables Unither Pharmaceuticals to support the selection of a format according to the product, treatment needs and target patient population.
Unither Pharmaceuticals combines these manufacturing technologies with dedicated ophthalmic development expertise, supporting customers from early-stage development through industrial scale-up and commercial manufacturing.

Unither Pharmaceuticals supports ophthalmic projects from early development through commercial manufacturing, with dedicated R&D teams and pilot capabilities supporting development and industrial transfer.
For ophthalmic development and manufacturing, Unither Pharmaceuticals has access to versatile tank systems and batch sizes ranging from 3 L to 2,000 L, enabling projects to progress from development activities toward industrial manufacturing.
This integrated approach helps maintain continuity between formulation development, scale-up and commercial production.

For preservative-free multidose (PFMD) products, sterility must be maintained throughout the in-use period without relying on preservatives. Unither Pharmaceuticals addresses this requirement through aseptic manufacturing and sterile fill-finish processes, supported by dedicated PFMD manufacturing capabilities.
Unither Pharmaceuticals’ PFMD offering includes established ophthalmic dispensing technologies such as Aptar Pharma OSD® and Nemera Novelia®, combined with sterile, preservative-free filling capabilities.
For multidose products containing preservatives, Unither Pharmaceuticals also provides dedicated aseptic filling capabilities for ophthalmic solutions and suspensions.

There is no single delivery format suited to every ophthalmic product. The appropriate choice between preservative-free multidose (PFMD), standard multidose (preserved), and sterile BFS single doses depends on factors including the indication, treatment duration and patient needs.
Unither Pharmaceuticals supports ophthalmic projects with complementary technologies and development capabilities, allowing the delivery format and manufacturing approach to be considered in relation to the specific requirements of the product and its intended use.